Literature DB >> 17021852

Calcineurin and Erk1/2-signaling pathways are involved in the antiapoptotic effect of cyclosporin A on astrocytes exposed to simulated ischemia in vitro.

Bozena Gabryel1, Anna Pudelko, Jakub Adamczyk, Ireneusz Fischer, Andrzej Malecki.   

Abstract

The present study focused on mechanisms involved in the anti-apoptotic effect of cyclosporin A (CsA) towards ischemic injured astrocytes in vitro [under combined oxygen glucose deprivation (OGD)]. We investigated whether this action might be mediated through activation of extracellular signal regulated kinases 1 and 2 (Erk1/2) or attenuation of calcineurin (CaN) by immunosuppressant in ischemic astrocytes. Additionally, the influence of CsA on phosphorylation of Akt kinase was determined. After 21 days of in vitro culture, astrocytes were subjected to OGD (for 8 h) and CsA (0.25-10 microM); 0.25 microM CsA distinctly stimulated the Erk1/2 pathway in astrocytes exposed to OGD. This protective effect of CsA was strongly associated with CaN inhibition, increased expression of anti-apoptotic factors such as Bcl-X(L) and NF-kappaB, as well as suppression of caspase-3 activity. Maximum p-Akt kinase expression was observed following treatment with 1 microM CsA. Finally, we also demonstrated that the beneficial effect of CsA at a concentration of 10 microM is related mainly to strong CaN inhibition. The results obtained suggest that, depending on the concentration used, CsA might act as a protective agent towards ischemia-injured astroglial cells through alternative intracellular pathways associated with increased p-Erk1/2 and p-Akt expression or CaN inactivation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17021852     DOI: 10.1007/s00210-006-0106-x

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  58 in total

1.  Ca2+-induced apoptosis through calcineurin dephosphorylation of BAD.

Authors:  H G Wang; N Pathan; I M Ethell; S Krajewski; Y Yamaguchi; F Shibasaki; F McKeon; T Bobo; T F Franke; J C Reed
Journal:  Science       Date:  1999-04-09       Impact factor: 47.728

2.  Regulation of ERK1 and ERK2 by glucose and peptide hormones in pancreatic beta cells.

Authors:  Don Arnette; Tara Beers Gibson; Michael C Lawrence; Bridgette January; Shih Khoo; Kathleen McGlynn; Colleen A Vanderbilt; Melanie H Cobb
Journal:  J Biol Chem       Date:  2003-06-02       Impact factor: 5.157

3.  Two-site interaction of nuclear factor of activated T cells with activated calcineurin.

Authors:  F J Garcia-Cozar; H Okamura; J F Aramburu; K T Shaw; L Pelletier; R Showalter; E Villafranca; A Rao
Journal:  J Biol Chem       Date:  1998-09-11       Impact factor: 5.157

Review 4.  Astrocytic functions and physiological reactions to injury: the potential to induce and/or exacerbate neuronal dysfunction--a forum position paper.

Authors:  M Aschner
Journal:  Neurotoxicology       Date:  1998-02       Impact factor: 4.294

Review 5.  PI3K: downstream AKTion blocks apoptosis.

Authors:  T F Franke; D R Kaplan; L C Cantley
Journal:  Cell       Date:  1997-02-21       Impact factor: 41.582

6.  Protective effect of systemic treatment with cyclosporine A after global ischemia in rats.

Authors:  R Sinigaglia-Coimbra; E A Cavalheiro; C Coimbra
Journal:  J Neurol Sci       Date:  2002-11-15       Impact factor: 3.181

7.  Cyclosporin A, but not FK506, prevents the downregulation of phosphorylated Akt after transient focal ischemia in the rat.

Authors:  T Yoshimoto; H Uchino; Q P He; P A Li; B K Siesjö
Journal:  Brain Res       Date:  2001-04-27       Impact factor: 3.252

8.  Oxidative stress is a critical mediator of the angiotensin II signal in human neutrophils: involvement of mitogen-activated protein kinase, calcineurin, and the transcription factor NF-kappaB.

Authors:  Rajaa El Bekay; Moisés Alvarez; Javier Monteseirín; Gonzalo Alba; Pedro Chacón; Antonio Vega; José Martin-Nieto; Juan Jiménez; Elizabeth Pintado; Francisco J Bedoya; Francisco Sobrino
Journal:  Blood       Date:  2003-03-27       Impact factor: 22.113

9.  Activation of ERK and suppression of calcineurin are interacting mechanisms of cardioprotection afforded by delta-opioid receptor activation.

Authors:  Yoshihiro Ikeda; Tetsuji Miura; Jun Sakamoto; Takayuki Miki; Masaya Tanno; Hironori Kobayashi; Katsuhiko Ohori; Akari Takahashi; Kazuaki Shimamoto
Journal:  Basic Res Cardiol       Date:  2006-04-17       Impact factor: 17.165

10.  Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction.

Authors:  B M Burgering; P J Coffer
Journal:  Nature       Date:  1995-08-17       Impact factor: 49.962

View more
  4 in total

1.  AKT inhibition-mediated dephosphorylation of TFE3 promotes overactive autophagy independent of MTORC1 in cadmium-exposed bone mesenchymal stem cells.

Authors:  Huifeng Pi; Min Li; Lingyun Zou; Min Yang; Ping Deng; Tengfei Fan; Menyu Liu; Li Tian; Manyu Tu; Jia Xie; Mengyan Chen; Huijuan Li; Yu Xi; Lei Zhang; Mindi He; Yonghui Lu; Chunhai Chen; Tao Zhang; Zheng Wang; Zhengping Yu; Feng Gao; Zhou Zhou
Journal:  Autophagy       Date:  2018-10-20       Impact factor: 16.016

2.  Effect of diabetes blood-stasis syndrome and Xuefu Zhuyu decoction on ROS-ERK1/2 signaling pathway in rat retina Müller cells.

Authors:  Xiaofeng Ye; Hui Ren; Tingting Jiang; Ting Zhang; Gang Li
Journal:  Cytotechnology       Date:  2020-02-28       Impact factor: 2.058

Review 3.  The Emerging Roles of the Calcineurin-Nuclear Factor of Activated T-Lymphocytes Pathway in Nervous System Functions and Diseases.

Authors:  Maulilio John Kipanyula; Wahabu Hamisi Kimaro; Paul F Seke Etet
Journal:  J Aging Res       Date:  2016-08-15

4.  Calcineurin A beta deficiency ameliorates HFD-induced hypothalamic astrocytosis in mice.

Authors:  Katrin Pfuhlmann; Sonja C Schriever; Beata Legutko; Peter Baumann; Luke Harrison; Dhiraj G Kabra; Emily Violette Baumgart; Matthias H Tschöp; Cristina Garcia-Caceres; Paul T Pfluger
Journal:  J Neuroinflammation       Date:  2018-02-08       Impact factor: 8.322

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.